Hasan Tahir
About
In The Last Decade
Hasan Tahir
81 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 95
- Rheumatology 1.0k
- Immunology 924
- Hematology 602
- Dermatology 152
- Surgery 92
Countries citing papers authored by Hasan Tahir
This map shows the geographic impact of Hasan Tahir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hasan Tahir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hasan Tahir more than expected).
Fields of papers citing papers by Hasan Tahir
This network shows the impact of papers produced by Hasan Tahir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hasan Tahir. The network helps show where Hasan Tahir may publish in the future.
Co-authorship network of co-authors of Hasan Tahir
This figure shows the co-authorship network connecting the top 25 collaborators of Hasan Tahir. A scholar is included among the top collaborators of Hasan Tahir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hasan Tahir. Hasan Tahir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 4 | |
| 3 | 0 | |
| 4 | 3 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 2 | |
| 8 | 4 | |
| 9 | 16 | |
| 10 | 16 | |
| 11 | 26 | |
| 12 | 2 | |
| 13 | 3 | |
| 14 | 1 | |
| 15 | 7 | |
| 16 | 58 | |
| 17 | Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives | 0 |
| 18 | 45 | |
| 19 | A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks | 1 |
| 20 | 27 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.